Vieira Rafael José, Sousa-Pinto Bernardo, Cardoso-Fernandes António, Jácome Cristina, Portela Diana, Amaral Rita, Sá-Sousa Ana, Pereira Ana Margarida, Bousquet Jean, Fonseca João Almeida
Department of Community Medicine, Information and Health Decision Sciences (MEDCIDS), Faculty of Medicine of the University of Porto, Porto, Portugal.
Centre for Health Technology and Services Research, Health Research Network (CINTESIS@RISE), Faculty of Medicine of the University of Porto, Porto, Portugal.
Clin Transl Allergy. 2022 Sep;12(9):e12194. doi: 10.1002/clt2.12194.
The Control of Allergic Rhinitis and Asthma Test (CARAT) is a patient-reported outcome measurement (PROM) assessing the control of asthma and allergic rhinitis (AR) at a 4 week interval. This systematic review aimed to evaluate the measurement properties of CARAT. Following PRISMA and COSMIN guidelines, we searched five bibliographic databases and retrieved studies concerning the development, assessment of properties, validation, and/or cultural adaption of CARAT. The studies' methodological quality, the quality of measurement properties, and the overall quality of evidence were assessed. We performed meta-analysis of CARAT measurement properties. We included 16 studies. Control of Allergic Rhinitis and Asthma Test displayed sufficient content validity and very good consistency (meta-analytical Cronbach alpha = 0.83; 95% CI = 0.80-0.86;I = 62.6%). Control of allergic rhinitis and Asthma Test meta-analytical intraclass correlation coefficient was 0.91 (95% CI = 0.64-0.98;I = 93.7%). It presented good construct validity, especially for correlations with Patient-reported outcome measures assessing asthma (absolute Spearman correlation coefficients range = 0.67-0.73; moderate quality of evidence), and good responsiveness. Its minimal important difference is 3.5. Overall, CARAT has good internal consistency, reliability, construct validity and responsiveness, despite the heterogeneous quality of evidence. Control of Allergic Rhinitis and Asthma Test can be used to assess the control of asthma and AR. As first of its kind, this meta-analysis of CARAT measurement properties sets a stronger level of evidence for asthma and/or AR control questionnaires.
变应性鼻炎和哮喘控制测试(CARAT)是一种患者报告结局测量工具(PROM),用于每隔4周评估哮喘和变应性鼻炎(AR)的控制情况。本系统评价旨在评估CARAT的测量特性。按照PRISMA和COSMIN指南,我们检索了五个文献数据库,并检索了有关CARAT的开发、特性评估、验证和/或文化适应性的研究。评估了研究的方法学质量、测量特性质量和证据的整体质量。我们对CARAT的测量特性进行了荟萃分析。我们纳入了16项研究。变应性鼻炎和哮喘控制测试显示出足够的内容效度和非常好的一致性(荟萃分析的Cronbach α = 0.83;95%CI = 0.80 - 0.86;I² = 62.6%)。变应性鼻炎和哮喘控制测试的荟萃分析组内相关系数为0.91(95%CI = 0.64 - 0.98;I² = 93.7%)。它具有良好的结构效度,特别是与评估哮喘的患者报告结局测量工具的相关性方面(绝对Spearman相关系数范围 = 0.67 - 0.73;证据质量中等),以及良好的反应度。其最小重要差异为3.5。总体而言,尽管证据质量存在异质性,但CARAT具有良好的内部一致性、可靠性、结构效度和反应度。变应性鼻炎和哮喘控制测试可用于评估哮喘和AR的控制情况。作为对CARAT测量特性的首次此类荟萃分析,为哮喘和/或AR控制问卷设定了更强的证据水平。